Terns Pharmaceuticals (NASDAQ:TERN – Get Free Report) is expected to release its earnings data before the market opens on ...

Terns Pharmaceuticals (TERN – Research Report) received a Hold rating and price target from William Blair analyst Andy Hsieh today. The ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Terns Pharmaceuticals (NasdaqGS:TERN) with a ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Delcath Systems (DCTH – Research Report), Axsome ...

Seasoned biotechnology CEO brings 25 years of strategic, operational and commercial expertiseFOSTER CITY, Calif., Feb. 20, ...

Equities researchers at William Blair started coverage on shares of Terns Pharmaceuticals (NASDAQ:TERN – Get Free Report) in a research note issued to investors on Friday, Marketbeat reports. The firm ...

Terns Pharmaceuticals' lead molecules, TERN-701 and TERN-601, face stiff competition from established and more effective treatments in CML and obesity markets. TERN-701's advantage of food ...

TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy ...

Terns Pharmaceuticals, Inc., a biopharmaceutical company focused on developing small-molecule therapies for serious diseases, announced the appointment of Andrew Gengos as its new chief financial ...

FOSTER CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage ...

(MENAFN- GlobeNewsWire - Nasdaq) TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 New TERN-701 data from ...